Go to homelogo

ERACODA

European Renal Association COVID-19 Database...

Description

The European Renal Association COVID-19 Database (ERACODA) was established on March 21, 2020. The mission of this dedicated COVID-19 KRT database was to gain as soon as possible insight in what the COVID-19 epidemic means for patients on KRT across E...

General Design

Type
Cohort study
Cohort type
Clinical cohort, Case only
Data collection type
Retrospective, Prospective
Design
Longitudinal
Design description
Data were collected from all adult patients (aged ≥18 years) with a functioning kidney allograft or on maintenance dialysis treatment who are diagnosed with COVID-19. The primary outcome of the study was vital status at day 28 after diagnosis. ERACODA contains granular data on a large set of patient characteristics (including demographics, primary kidney disease, comorbidities, clinical frailty score, and medication use) and COVID-19 characteristics (including symptoms, vital signs, and laboratory test results). In addition, quality of life related outcome measures were collected. Physicians were asked whether their patients have reached their pre-COVID-19 functional and mental status 3 months after initial presentation. If this is not the case, further questions address the expected recovery and potential factors limiting recovery. The data collection was stopped by March 1st, 2022.
Start/End data collection
2020 until 2022
PID
https://doi.org/10.34760/6526645b80fc4

Population

Countries
United States of America (the), United Kingdom of Great Britain and Northern Ireland (the), Ukraine, Turkey, Switzerland, Slovenia, Slovakia, Serbia, Russian Federation (the), Romania, Norway, Netherlands (the), Morocco, Luxembourg, Lithuania, Japan, Italy, Israel, India, Greece, Germany, France, Finland, Egypt, Czechia, Croatia, Brazil, Bosnia and Herzegovina, Belgium
Number of participants
5258
Number of participants with samples
0
Population age groups
Adult (18+ years)
Other inclusion criteria
Adult patients (aged ≥18 years) with a functioning kidney allograft or on maintenance dialysis treatment who are diagnosed with COVID-19. The COVID-19 diagnosis needed to be based on a positive result on a real-time polymerase chain reaction (PCR) assay of nasal or pharyngeal swab specimens, and/or compatible findings on a computer tomography (CT) scan or chest X-ray of the lungs. Data from both outpatient and hospitalized patients were collected.

Organisations

Lead organisations
Additional organisations

Contributors

Available Data & Samples

Data categories

  • Biological samples
  • Imaging data
  • Medical records
  • Physiological/Biochemical measurements

Sample categories

  • Blood

Areas of information

  • Socio-demographic and economic characteristics
  • Lifestyle and behaviours
  • Perception of health, quality of life, development and functional limitations
  • Medication and supplements
  • Non-pharmacological interventions
  • Death
  • Physical measures and assessments
  • Laboratory measures

Subpopulations

List of subpopulations for this resource...

No results for current selection

Collection events

List of collection events defined for this resource...

No results for current selection

Access conditions

Data Sharing Statement: Collaborators that entered data in ERACODA remain owner of these data. The database can therefore not be disclosed to any third party without the prior written consent of all data providers....

Data access conditions
health or medical or biomedical research
Data use conditions
  • collaboration required
  • user specific restriction
Data access fee
false
Release type
Closed dataset
Release description
-
Linkage options
-

Funding & Acknowledgements

Funding
Unrestricted research grants were obtained from the European Renal Association (ERA), the Dutch Kidney Foundation, Baxter and Sandoz.
Acknowledgements
We thank all people that entered information in the ERACODA database for their participation, and especially all healthcare workers that have taken care of the included COVID-19 patients. The ERACODA collaboration is an initiative to study prognosis and risk factors for mortality due to COVID-19 in patients with a kidney transplant or on dialysis that is endorsed by the ERA. The organizational structure contains a Working Group assisted by a Management Team and Advisory Board. ERACODA Working Group: Franssen CFM, Gansevoort RT (coordinator), Hemmelder MH, Hilbrands LB and Jager KJ. ERACODA Management Team: Duivenvoorden R, Noordzij M, Vart P. ERACODA Advisory Board: Abramowicz D, Basile C, Covic A, Crespo M, Massy ZA, Mitra S, Petridou E, Sanchez JE, White C.

Created with MOLGENIS